Swedbank AB lowered shares of AstraZeneca (LON: AZN) to a sell rating in a research report released on Friday morning. Swedbank AB currently has $40.22 (2693 GBX) price target on the stock.

AstraZeneca opened at 3052.00 on Friday. AstraZeneca has a 1-year low of GBX 2578.50 and a 1-year high of GBX 3171.50. The stock’s 50-day moving average is currently GBX 2919.40. The company’s market cap is £38.058 billion.

Several other analysts have also recently commented on the stock. Analysts at Deutsche Bank reiterated a hold rating on shares of AstraZeneca in a research note to investors on Thursday, March 7th. They now have a $42.09 price target on the stock. Separately, analysts at Panmure Gordon reiterated a hold rating on shares of AstraZeneca in a research note to investors on Tuesday, March 5th. They now have a $45.10 price target on the stock. Finally, analysts at Goldman Sachs reiterated a neutral rating on shares of AstraZeneca in a research note to investors on Tuesday, March 5th. They now have a $50.74 price target on the stock.

AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. AstraZeneca discovers, develops and commercializes prescription medicines for six areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.